Ho Woon Fei

Isthmin-1 attenuates allergic Asthma by stimulating adiponectin expression and alveolar macrophage efferocytosis in mice

Isthmin-1 attenuates allergic Asthma by stimulating adiponectin expression and alveolar macrophage efferocytosis in mice

Jong Huat Tee, Udhaya Vijayakumar, Mahalakshmi Shanmugasundaram, Terence Y. W. Lam, Wupeng Liao, Yuansheng Yang, W. S. Fred Wong* and Ruowen Ge*

Abstract
Background Allergic asthma is a common respiratory disease that significantly impacts human health. Through in silico analysis of human lung RNASeq, we found that asthmatic lungs display lower levels of Isthmin-1 (ISM1) expression than healthy lungs. ISM1 is an endogenous anti-inflammatory protein that is highly expressed in mouse lungs and bronchial epithelial cells, playing a crucial role in maintaining lung homeostasis. However, how ISM1 influences asthma remains unclear. This study aims to investigate the potential involvement of ISM1 in allergic airway inflammation and uncover the underlying mechanisms.

Methods  We investigated the pivotal role of ISM1 in airway inflammation using an ISM1 knockout mouse line (ISM1−/−) and challenged them with house dust mite (HDM) extract to induce allergic-like airway/lung inflammation. To examine the impact of ISM1 deficiency, we analyzed the infiltration of immune cells into the lungs and cytokine levels in bronchoalveolar lavage fluid (BALF) using flow cytometry and multiplex ELISA, respectively. Furthermore, we examined the therapeutic potential of ISM1 by administering recombinant ISM1 (rISM1) via the intratracheal route to rescue the effects of ISM1 reduction in HDM-challenged mice. RNA-Seq, western blot, and fluorescence microscopy techniques were subsequently used to elucidate the underlying mechanisms.

Results  ISM1−/− mice showed a pronounced worsening of allergic airway inflammation and hyperresponsiveness upon HDM challenge. The heightened inflammation in ISM1−/− mice correlated with enhanced lung cell necroptosis, as indicated by higher pMLKL expression. Intratracheal delivery of rISM1 significantly reduced the number of eosinophils in BALF and goblet cell hyperplasia. Mechanistically, ISM1 stimulates adiponectin secretion by type 2 alveolar epithelial cells partially through the GRP78 receptor and enhances adiponectin-facilitated apoptotic cell clearance via alveolar macrophage efferocytosis. Reduced adiponectin expression under ISM1 deficiency also contributed to intensified necroptosis, prolonged inflammation, and heightened severity of airway hyperresponsiveness.

Conclusions  This study revealed for the first time that ISM1 functions to restrain airway hyperresponsiveness to HDM-triggered allergic-like airway/lung inflammation in mice, consistent with its persistent downregulation in human asthma. Direct administration of rISM1 into the airway alleviates airway inflammation and promotes immune cell clearance, likely by stimulating airway adiponectin production. These findings suggest that ISM1 has therapeutic potential for allergic asthma.

Isthmin-1 attenuates allergic Asthma by stimulating adiponectin expression and alveolar macrophage efferocytosis in mice Read More »

Department of Pharmacology researchers featured in “Decoding the Brain”

In a new Hello Singapore feature segment titled “解密大脑” (Decoding the Brain) on Channel 8, researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) explain the functions of the human brain and its multiple stages of growth and development, and aim to use scientific reasoning to debunk common myths about the human brain.

From cognitive abilities to memory enhancement and retention, viewers will be able to understand the intricate process of how short-term memory progresses to become long-term memory, as explained by Assoc Prof Sajikumar from the Synaptic Plasticity and Memory Lab.

Premonition versus intuition – Dr Eric Tan from the Memory, Ageing and Cognition Centre (also from Department of Pharmacology) offers the science behind experiencing a premonition.

Research Fellows Dr Yap Kwong Hsia and Dr Joyce Chong (both from Department of Pharmacology) elaborate how the multi-domain lifestyle interventions in the SINGER study have proven to slow down the rate of Alzheimer’s disease in the elderly.

Department of Pharmacology researchers featured in “Decoding the Brain” Read More »

Congratulations to Faculty Recognized Among Top 2% of Scientists Worldwide

The Department of Pharmacology congratulates 18 faculty members on being recognized among the top 2% of scientists worldwide for citation impact in 2023. The analysis was initiated by Professor Ioannidis at Stanford University and published by Elsevier.

Congratulations to faculty members Professor Fred Wong Wai-Shiu, Professor Dean Ho, Professor Goh Boon Cher, Associate Professor Gautam Sethi, Associate Professor Christopher Chen Li-Hsian, Dr Alan Prem Kumar; joint faculty members Professor Guillermo C. Bazan, Professor R. Manjunatha Kini, Professor Philip Keith Moore, A/Prof Wang Lingzhi, Dr Muthu Kumaraswamy Shanmugam, Dr Saima Hilal; adjunct faculty members Associate Professor Edward J. Manser, Associate Professor Shabbir Moochhala; retired faculty members Emeritus Professor Edmund Lee Jon Deoon, Associate Professor Benny Tan Kwon Huat; and visiting professors Professor Jerold Chun and Professor Paul Foster.  

To view the full list of the world’s top 2% researchers by citation impact published on 4 October 2023 by Elsevier see https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/6.

Congratulations to Faculty Recognized Among Top 2% of Scientists Worldwide Read More »

1st Prize Winner of Slips, Trips and Falls Campaign Creative Video Competition: CHEONG Yoke Ping and DSHC Team

Congratulations to CHEONG Yoke Ping and Department of Pharmacology Safety and Health Team on winning the Slips, Trips and Falls Campaign Creative Video Competition!

Pharmacology Team Members:

CHEONG Yoke Ping (Project Leader), Alan KOH, Annie HSU, CHOU Loi Choo, Christabel CHAN Mei Yun, FAN Lu, HO Woon Fei, LAW Yok Moi, Pawan KUMAR, TAN Yen Ling, TEO Mei Hui, TEO Wee Lee, XU Xiaoguang  and Kenneth YAP.

 

1st Prize Winner of Slips, Trips and Falls Campaign Creative Video Competition: CHEONG Yoke Ping and DSHC Team Read More »

2023 NUSMed Excellence in Administration Awards (Merit Award): PHARMACOLOGY

Congratulations to Department of Pharmacology Team on being selected as the winner of 2023 NUSMed Excellence in Administration Awards.

Pharmacology Team Members:

CHEONG Yoke Ping (Project Leader), Alan KOH (Project Co-Leader), Annie HSU, CHOU Loi Choo, Christabel CHAN Mei Yun, FAN Lu, HO Woon Fei, LAW Yok Moi, Pawan KUMAR, TAN Yen Ling, TEO Wee Lee, XU Xiaoguang

 

2023 NUSMed Excellence in Administration Awards (Merit Award): PHARMACOLOGY Read More »

Awardee of The Distinguished Senior Clinician Award 2023: Prof GOH Boon Cher

Congratulations to Professor GOH Boon Cher on receiving the Distinguished Senior Clinician Award 2023.

The Distinguished Senior Clinician Award (DSCA) is a prestigious accolade conferred by the Ministry of Health to recognise experts  and key opinion leaders in their professional fields.

They serve as role models with strong public service values, professional integrity, and have made outstanding contributions in the domain areas of clinical practice, education and research.

As a senior clinician, Prof Goh has held critical leadership roles at institutional and national levels, including the founding Director of the lnvestigational Medicine Unit at NUHS; Deputy Director of the National University Cancer Institute, Singapore (NCISI; Clinical trials co-lead at the Singapore Translational Cancer Consortium; Deputy Di rector of the Cancer Science Institute of Singapore, NUS; Clinical Research Institute, NUS; Head of the Department of Haematology-Oncology, NCIS; and Deputy Director of the NUS Cancer Translational research program. At NCIS, he established a world-renowned clinical trial programme, now with over 150 clinical trials, which is a testament to his pioneering vision. Internationally, as a key opinion leader, he has served on advisory boards of several pharmaceutical companies advising on drug development of very novel drugs and has served on editorial boards of important journals like the Journal of Clinical Oncology and Annals of Oncology.

Awardee of The Distinguished Senior Clinician Award 2023: Prof GOH Boon Cher Read More »

Multifunctional Antibacterial Nanonets Attenuate Inflammatory Responses through Selective Trapping of Endotoxins and Pro-Inflammatory Cytokines

Multifunctional Antibacterial Nanonets Attenuate Inflammatory Responses through Selective Trapping of
Endotoxins and Pro-Inflammatory Cytokines

Nhan Dai Thien Tram, Quy Thi Ngoc Tran, Jian Xu, Jeannie Ching Ting Su, Wupeng Liao, Wai Shiu Fred Wong, and Pui Lai Rachel Ee*

Extracellular lipopolysaccharide (LPS) released from bacteria cells can enter the bloodstream and cause septic complications with excessive host inflammatory responses. Target-specific strategies to inactivate inflammation mediators have largely failed to improve the prognosis of septic patients in clinical trials. By utilizing their high density of positive charges, de novo
designed peptide nanonets are shown to selectively entrap the negatively charged LPS and pro-inflammatory cytokines tumor necrosis factor-𝜶 (TNF-𝜶) and interleukin-6 (IL-6). This in turn enables the nanonets to suppress LPS-induced cytokine production by murine macrophage cell line and rescue the antimicrobial activity of the last-resort antibiotic, colistin, from LPS
binding. Using an acute lung injury model in mice, it is demonstrated that intratracheal administration of the fibrillating peptides is effective at lowering local release of TNF-𝜶 and IL-6. Together with previously shown ability to simultaneously trap and kill pathogenic bacteria, the peptide nanonets display remarkable potential as a holistic, multifunctional anti-infective, and
anti-septic biomaterial.

Multifunctional Antibacterial Nanonets Attenuate Inflammatory Responses through Selective Trapping of Endotoxins and Pro-Inflammatory Cytokines Read More »

Degradation of MK2 with natural compound andrographolide: A new modality for anti-inflammatory therapy

Degradation of MK2 with natural compound andrographolide: A new modality for anti-inflammatory therapy

Quy T.N. Tran a,b,c,1, Phyllis X.L. Gan a,2, Wupeng Liao a,d,3, Yu Keung Mok e,4, Christina L.L. Chai b,c,*,5, W.S. Fred Wong

a Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, 117600, Singapore
b Department of Pharmacy, Faculty of Science, National University of Singapore, 117543, Singapore
c Drug Discovery and Optimization Platform (DDOP), Yong Loo Lin School of Medicine, National University Health System, 117600, Singapore
d Singapore-HUJ Alliance for Research and Enterprise (SHARE), National University of Singapore, Singapore
e Department of Biological Sciences, Faculty of Science, National University of Singapore, 117543, Singapore

A B S T R A C T

The p38MAPK-MK2 signaling axis functions as an initiator of inflammation. Targeting the p38MAPK-MK2 signaling axis represents a direct therapeutic intervention of inflammatory diseases. We described here a novel role of andrographolide (AG), a small-molecule ent-labdane natural compound, as an inhibitor of p38MAPK-MK2 axis via MK2 degradation. AG was found to bind to the activation loop of MK2, located at the interface of the p38MAPKMK2 biomolecular complex. This interaction disrupted the complex formation and predisposed MK2 to proteasome-mediated degradation. We showed that AG induced MK2 degradation in a concentration- and timedependent manner and exerted its anti-inflammatory effects by enhancing the mRNA-destabilizing activity of tristetraprolin, thereby inhibiting pro-inflammatory mediator production (e.g., TNF-α, MCP-1). Administration of AG via intratracheal (i.t.) route to mice induced MK2 downregulation in lung alveolar macrophages, but not lung tissues, and prevented macrophage activation. Our study also demonstrated that the anti-inflammatory effects achieved by AG via MK2 degradation were more durable and sustained than that achieved by the conventional MK2 kinase inhibitors (e.g., PF-3644022). Taken together, our findings illustrated a novel mode of action of AG by modulating the p38MAPK-MK2 signaling axis and would pave the way for the development of a novel class of anti-inflammatory agents targeting MK2 for degradation by harnessing the privileged scaffold of AG.

Degradation of MK2 with natural compound andrographolide: A new modality for anti-inflammatory therapy Read More »

Appointment of Dr Alan Prem Kumar as Assistant Dean (Graduate Studies), Yong Loo Lin School of Medicine, National University of Singapore

Congratulation to Dr Alan Prem Kumar on his appointment as Assistant Dean (Graduate Studies) at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) with effect from 1 September 2023!

In addition to his academic position, Dr Kumar currently holds two administrative leadership roles in NUS Medicine. He is the Deputy Director, Office of Postdoctoral Affairs, in the Division of Graduate Studies. The Office of Postdoctoral Affairs aims to improve interdisciplinary cooperation and build strategic connections to strengthen our postdoctoral community. Dr Kumar is also the Academic Outreach Lead within the Research Office, working closely with Associate Professor Veronique Angeli (Assistant Dean, Academic Strategy), to build productive partnerships with external institutions and industries. Dr Kumar is a Recipient of the NUS Medicine Graduate Mentor of the Year Award 2017 and 2021 for excellence in supervision, intellectual and professional development of graduate students. His research is focused on uncovering new cues that drive the spread of cancer and develop target-based precision therapies to prevent metastasis in female reproductive cancers. His contribution to translational research gained him the Recipient of World’s Highly Cited Researchers by Clarivate for the past three years. Dr Kumar also sits on the Scientific Advisory Boards for GenoMed, Inc., USA (Oncology Markers); Sansad Mobile Swasthya Seva Healthcare Programme, Parliament of India, India (Breast Cancer Awareness and Screening); The Sparks Foundation, Singapore (Education); and AUM Biosciences, Singapore (Oncology Drug Acquisitions).

In his role as the Assistant Dean (Graduate Studies), Dr Kumar will join A/P Tan Shyong Wei, Vice-Dean (Graduate Studies) in managing all matters related to postdoctoral community in NUS Medicine. He will also play a vital role in fostering strong links between the postdoctoral fellows and PhD students, and junior clinician scientist communities, to create a vibrant academic community.

Appointment of Dr Alan Prem Kumar as Assistant Dean (Graduate Studies), Yong Loo Lin School of Medicine, National University of Singapore Read More »